Profile data is unavailable for this security.
About the company
Thermo Fisher Scientific Inc. is engaged in helping life sciences research, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. It also provides proteomics solutions. Analytical Instruments segment provides instruments and the supporting consumables, software and services that are used for a range of applications in the laboratory and in the field. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial and others. Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory.
- Revenue in USD (TTM)42.35bn
- Net income in USD6.22bn
- Incorporated1960
- Employees122.00k
- LocationThermo Fisher Scientific Inc168 Third AvenueWALTHAM 02451United StatesUSA
- Phone+1 (781) 622-1000
- Fax+1 (781) 622-1207
- Websitehttps://www.thermofisher.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cencora Inc | 283.83bn | 1.86bn | 47.21bn | 42.00k | 26.01 | 51.01 | 15.82 | 0.1663 | 9.21 | 9.21 | 1,407.82 | 4.70 | 4.44 | 15.60 | 11.97 | 6,757,877.00 | 2.91 | 0.9542 | 13.38 | 3.95 | 3.37 | 3.14 | 0.6556 | 0.2178 | 0.5476 | 14.76 | 0.8169 | 76.85 | 9.89 | 9.32 | 2.74 | 10.79 | 6.38 | 5.00 |
| Becton Dickinson and Co | 19.83bn | 1.46bn | 70.07bn | 73.00k | 48.34 | 2.71 | 18.70 | 3.53 | 5.01 | 4.86 | 67.99 | 89.50 | 0.3652 | 3.17 | 7.92 | 271,616.40 | 2.69 | 2.37 | 3.07 | 2.70 | 45.35 | 45.78 | 7.36 | 6.95 | 1.36 | 8.42 | 0.4276 | 81.23 | 2.66 | 3.92 | -4.85 | 12.97 | -0.4737 | 3.94 |
| Medtronic PLC | 32.58bn | 3.93bn | 113.60bn | 95.00k | 29.79 | 2.37 | 17.24 | 3.49 | 2.97 | 2.97 | 24.66 | 37.39 | 0.3609 | 2.03 | 5.51 | 342,915.80 | 4.38 | 4.57 | 4.92 | 5.14 | 65.53 | 66.75 | 12.14 | 13.49 | 1.61 | 12.10 | 0.3665 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.23bn | 1.83bn | 120.45bn | 48.00k | 66.13 | 5.91 | 39.45 | 7.91 | 1.24 | 1.24 | 10.29 | 13.85 | 0.4307 | 1.94 | 6.72 | 317,250.00 | 5.16 | 2.50 | 6.07 | 2.91 | 69.08 | 68.84 | 11.98 | 6.47 | 1.14 | 5.73 | 0.339 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.39bn | 3.45bn | 137.30bn | 52.00k | 40.19 | 6.95 | 30.66 | 6.42 | 8.97 | 8.97 | 55.62 | 51.86 | 0.5589 | 1.60 | 6.22 | 411,326.90 | 9.01 | 6.60 | 10.94 | 7.84 | 64.05 | 63.99 | 16.12 | 13.13 | 0.9531 | -- | 0.3821 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Intuitive Surgical, Inc. | 7.57bn | 2.09bn | 174.74bn | 13.68k | 84.59 | 11.90 | 67.26 | 23.08 | 5.82 | 5.82 | 21.06 | 41.40 | 0.4957 | 2.10 | 7.52 | 553,707.30 | 13.81 | 12.42 | 15.42 | 13.83 | 66.86 | 67.60 | 27.86 | 26.31 | 4.22 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Danaher Corp | 23.57bn | 4.06bn | 194.50bn | 61.00k | 49.52 | 3.91 | 31.03 | 8.25 | 5.44 | 5.63 | 31.63 | 68.92 | 0.2884 | 3.29 | 6.23 | 386,360.70 | 4.96 | 5.93 | 5.47 | 6.56 | 59.16 | 58.79 | 17.21 | 19.11 | 1.04 | 17.19 | 0.2542 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Abbott Laboratories | 40.73bn | 5.56bn | 197.08bn | 114.00k | 35.64 | 5.01 | 22.39 | 4.84 | 3.18 | 3.18 | 23.29 | 22.60 | 0.5565 | 2.65 | 6.25 | 357,236.80 | 7.59 | 7.72 | 9.44 | 9.39 | 55.43 | 56.73 | 13.65 | 14.39 | 1.18 | 25.44 | 0.2716 | 54.95 | -8.12 | 5.58 | -17.45 | 18.36 | 9.57 | 12.74 |
| Thermo Fisher Scientific Inc | 42.35bn | 6.22bn | 234.95bn | 122.00k | 38.15 | 4.95 | 24.52 | 5.55 | 16.12 | 16.12 | 109.78 | 124.17 | 0.4397 | 4.62 | 4.48 | 347,098.40 | 6.50 | 7.79 | 7.66 | 9.11 | 40.76 | 44.94 | 14.79 | 16.76 | 1.37 | 22.89 | 0.4269 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 31.08m | 8.14% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 16.99m | 4.45% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 16.19m | 4.24% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 9.52m | 2.49% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 9.36m | 2.45% |
| Capital Research & Management Co. (Global Investors)as of 30 Jun 2024 | 8.24m | 2.16% |
| Geode Capital Management LLCas of 30 Jun 2024 | 7.53m | 1.97% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 5.57m | 1.46% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 5.21m | 1.36% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 4.37m | 1.15% |
